Protein / target
Alpha-2A adrenergic receptor
Protein at a glance
Biological role
Alpha-1B adrenergic receptor binding
Primary system
Nervous system
Strongest disease association
asthma
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
47 approved · 8 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression (PubMed:2170371, PubMed:23105096, PubMed:2568356, PubMed:35245122, PubMed:27376152). Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release (PubMed:2568356, PubMed:27376152). ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity (By similarity). The rank order of potency for agonists of ADRA2A is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianserine > chlorpromazine = spiperone = prazosin > propanolol > alprenolol = pindolol (PubMed:2170371, PubMed:2568356)
Subcellular location
Domains and Gene Ontology detail (60)Hide
Gene Ontology
- Caxon terminus
- Cbasolateral plasma membrane
- Ccytoplasm
- Cdopaminergic synapse
- CGABA-ergic synapse
- Cglutamatergic synapse
- Cneuronal cell body
- Cplasma membrane
- Cpostsynaptic density membrane
- Cpresynaptic active zone membrane
- Creceptor complex
- Falpha-1B adrenergic receptor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that act…
- ·dopaminergic synapse
- ·GABA-ergic synapse
- ·glutamatergic synapse
G protein-coupled signalling
- ·Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that act…
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
- ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
- ·G protein-coupled receptor signaling pathway
Kinase signalling
- ·protein kinase binding
- ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Inhibitory neurotransmission
- ·GABA-ergic synapse
Excitatory neurotransmission
- ·glutamatergic synapse
Immune signalling
- ·positive regulation of cytokine production
View underlying pathways (6)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Adrenergic receptor agonist
Appears in clinical studies involving sudden cardiac arrest, asthma, sinusitis, septic shock
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 568 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 57 total
neuropathic pain · Pain
hypertensive disorder · attention deficit-hyperactivity disorder · attention deficit-hyperactivity disorder
hypotensive disorder · asthma
Horner syndrome
hypertensive disorder · essential hypertension
opiate dependence · drug dependence · cannabis dependence
Hypertension
Irritability · sedation · congenital heart disease
Headache · migraine disorder
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Label change
Label change: EPINEPHRINE (NDA204640)
- Product recall
Recall (Class III): EPINEPHRINE
- Regulatory approval
Approval: Eurneffy (EMA)
- New publicationImpact of norepinephrine on immunity and oxidative metabolism in sepsis.
- Label change
Label change: EPINEPHRINE (NDA204640)
- Supplemental approval
Supplemental approval: EPINEPHRINE (NDA204640)
- New publicationThe effect of topical epinephrine 1:1000 with and without infiltration of 1% lidocaine with epinephrine 1:100,000 on endoscopic surgical field visualization: a double-blind randomized controlled study.
- Indication expanded
Indication expansion: EPINEPHRINE (NDA204640)
- Label change
Label change: EPINEPHRINE (NDA204640)
- Label change
Label change: EPINEPHRINE (NDA204640)
- Supplemental approval
Supplemental approval: EPINEPHRINE (NDA204640)
- Regulatory approval
Approval: EPINEPHRINE (NDA204640)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.